Alector Inc

NASDAQ:ALEC   3:59:54 PM EDT
23.58
-0.15 (-0.63%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.90B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$22.63 Million
Adjusted EPS-$0.50
See more estimates
10-Day MA$23.49
50-Day MA$24.78
200-Day MA$21.96
See more pivots

Alector Inc Stock, NASDAQ:ALEC

131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080
United States of America
Phone: +1.415.231.5660
Number of Employees: 171

Description

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.